Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermtech Inc (NQ: DMTK )

2.451 +0.071 (+3.00%)
Streaming Delayed Price Updated: 3:42 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dermtech Inc

< Previous 1 2 3 4 5 6 Next >
DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring, But Not Yet Talking About
Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities. Retail traders have countless methods at their disposal to uncover new information. For some, this... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to Run
This beaten-down healthcare stock has started the new year off with a bang. 
Via The Motley Fool
DermTech Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Crude Oil Rises Over 1%; Oak Street Health Shares Spike Higher
U.S. stocks traded slightly higher midway through trading, with the Dow Jones around than 30 points on Tuesday. 
Via Benzinga
US Stocks Open Higher; Nasdaq Rises 50 Points
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 50 points on Tuesday. 
Via Benzinga
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE
From DermTech, Inc.
Via Business Wire
DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test
From DermTech, Inc.
Via Business Wire
Analyst Ratings for DermTech
Over the past 3 months, 4 analysts have published their opinion on DermTech (NASDAQ:DMTK) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Cidara Therapeutics (NASDAQ:CDTX) shares rose 14.6% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. The company's, Q3 earnings... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
DermTech Reports Third-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Gainers 
Via Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Upgrades 
Via Benzinga
DermTech Announces Release Date for Third-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern California
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, DermTech's (NASDAQ:DMTK) reported sales totaled $4.23 million. Despite a 1.75% increase in earnings, the company posted a loss of $29.58 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.